Francis Medical Inc.
Francis Medical is a medical device company developing a transurethral water‑vapor thermal ablation system for focal treatment of urological cancers (prostate, with development for kidney and bladder). The company has conducted early feasibility and pivotal multicenter clinical studies (VAPOR 1, VAPOR 2), received FDA Breakthrough Device designation for early work, and pursued regulatory clearance and U.S. commercialization while supporting physician training, perioperative guidance, and reimbursement support. The device is marketed as a prescription-only tool for transurethral thermal ablation and operator training is required prior to use.
Industries
Nr. of Employees
small (1-50)
Products
Transurethral water‑vapor thermal ablation system
A medical device system that delivers stored thermal energy in the form of sterile water vapor via a transurethral approach to ablate targeted prostate tissue under ultrasound guidance for focal outpatient treatment.
Vanquish System
A system that includes capital, disposables and an informative user interface that displays recorded MRI images with real-time ultrasound and cystoscopy to support targeted ablation of prostate tissue.
Transurethral water‑vapor thermal ablation system
A medical device system that delivers stored thermal energy in the form of sterile water vapor via a transurethral approach to ablate targeted prostate tissue under ultrasound guidance for focal outpatient treatment.
Vanquish System
A system that includes capital, disposables and an informative user interface that displays recorded MRI images with real-time ultrasound and cystoscopy to support targeted ablation of prostate tissue.
Services
Mandatory device and procedural training for physicians and clinical teams to support safe use and clinical adoption.
Provision of coding guidance, example prior‑authorization templates and Medicare/CPT/HCPCS reference material to support billing and coverage discussions.
Mandatory device and procedural training for physicians and clinical teams to support safe use and clinical adoption.
Provision of coding guidance, example prior‑authorization templates and Medicare/CPT/HCPCS reference material to support billing and coverage discussions.
Expertise Areas
- Minimally invasive device development for urological applications
- Clinical trial management and multicenter pivotal studies
- Regulatory strategy and US market submissions
- Commercialization planning and fundraising for medical devices
Key Technologies
- Thermal water‑vapor ablation (phase‑change convective heat transfer)
- Transurethral delivery systems and catheter-based applicators
- Ultrasound-guided focal therapy
- Minimally invasive outpatient procedural platforms
News & Updates
Announcement of an oversubscribed $80M Series C round to fund the VAPOR 2 pivotal clinical study and U.S. commercialization efforts.
Announcement of completion of $55M Series B financing to fund development toward regulatory submissions and the VAPOR 2 pivotal study.
Company launch announcement and completion of $18M Series A financing to support international clinical work and preparation for early clinical studies.
Peer‑reviewed report of transurethral vapor ablation in a prospective, single‑arm study assessing safety and oncologic results.
Publication of initial VAPOR 2 pivotal trial results reporting safety and patient‑reported outcomes.
Presentation of initial VAPOR 2 study results at a focal therapy conference.
Announcement of an oversubscribed $80M Series C round to fund the VAPOR 2 pivotal clinical study and U.S. commercialization efforts.
Announcement of completion of $55M Series B financing to fund development toward regulatory submissions and the VAPOR 2 pivotal study.
Company launch announcement and completion of $18M Series A financing to support international clinical work and preparation for early clinical studies.
Peer‑reviewed report of transurethral vapor ablation in a prospective, single‑arm study assessing safety and oncologic results.
Publication of initial VAPOR 2 pivotal trial results reporting safety and patient‑reported outcomes.
Presentation of initial VAPOR 2 study results at a focal therapy conference.